A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

Joshua S. Woodworth, Helena Strand Clemmensen, Hannah Battey, Karin Dijkman, Thomas Lindenstrøm, Raquel Salvador Laureano, Randy Taplitz, Jeffrey Morgan, Claus Aagaard, Ida Rosenkrands, Cecilia S. Lindestam Arlehamn, Peter Andersen and Rasmus Mortensen ()
Additional contact information
Joshua S. Woodworth: Statens Serum Institut
Helena Strand Clemmensen: Statens Serum Institut
Hannah Battey: Statens Serum Institut
Karin Dijkman: Statens Serum Institut
Thomas Lindenstrøm: Statens Serum Institut
Raquel Salvador Laureano: Statens Serum Institut
Randy Taplitz: University of California San Diego
Jeffrey Morgan: La Jolla Institute for Immunology
Claus Aagaard: Statens Serum Institut
Ida Rosenkrands: Statens Serum Institut
Cecilia S. Lindestam Arlehamn: La Jolla Institute for Immunology
Peter Andersen: Statens Serum Institut
Rasmus Mortensen: Statens Serum Institut

Nature Communications, 2021, vol. 12, issue 1, 1-13

Abstract: Abstract Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26934-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26934-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26934-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().